Artículos por temáticas

Levodopa Effect on Basal Ganglia Motor Circuit in Parkinson's Disease.

Gao LL, Zhang JR, Chan P, Wu T.

CNS Neurosci Ther. 2017 Jan;23(1):76-86. doi: 10.1111/cns.12634.

The Perceive, Recall, Plan and Perform (PRPP) system for persons with Parkinson's disease: a psychometric study.

Van Keulen-Rouweler BJ, Sturkenboom IH, Kottorp A, Graff MJ, Nijhuis-Van der Sanden MW, Steultjens EM.

Scand J Occup Ther. 2017 Jan;24(1):65-73. doi: 10.1080/11038128.2016.1233291.

Pathological gambling in Parkinson's disease: what are the risk factors and what is the role of impulsivity?

Heiden P, Heinz A, Romanczuk-Seiferth N.

Eur J Neurosci. 2017 Jan;45(1):67-72. doi: 10.1111/ejn.13396. Review.

Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands.

Kirik D, Cederfjäll E, Halliday G, Petersén Å.

Neurobiol Dis. 2017 Jan;97(Pt B):179-188. doi: 10.1016/j.nbd.2016.09.008. Review.

Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats.

Naughton C, O'Toole D, Kirik D, Dowd E.

Behav Brain Res. 2017 Jan 1;316:160-168. doi: 10.1016/j.bbr.2016.08.056.

Group singing and health-related quality of life in Parkinson's disease.

Abell RV, Baird AD, Chalmers KA.

Health Psychol. 2017 Jan;36(1):55-64. doi: 10.1037/hea0000412.

Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes.

Cho SS, Aminian K, Li C, Lang AE, Houle S, Strafella AP.

Hum Brain Mapp. 2017 Jan;38(1):283-292. doi: 10.1002/hbm.23360.

Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.

Kish SJ, Boileau I, Callaghan RC, Tong J.

Eur J Neurosci. 2017 Jan;45(1):58-66. doi: 10.1111/ejn.13363. Review.

Esophageal dysfunction in different stages of Parkinson's disease.

Suttrup I, Suttrup J, Suntrup-Krueger S, Siemer ML, Bauer J, Hamacher C, Oelenberg S, Domagk D, Dziewas R, Warnecke T.

Neurogastroenterol Motil. 2017 Jan;29(1). doi: 10.1111/nmo.12915.

The effect of L-dopa in Parkinson's disease as revealed by neurophysiological studies of motor and sensory functions.

Suppa A, Bologna M, Conte A, Berardelli A, Fabbrini G.

Expert Rev Neurother. 2017 Feb;17(2):181-192. doi: 10.1080/14737175.2016.1219251.

Treatment of a female patient with persistent genital arousal and Parkinson's disease with paliperidone.

Fountoulakis KN, Tegos T, Goulis DG, Nimatoudis I, Kimiskidis V.

Aust N Z J Psychiatry. 2017 Jan;51(1):98-99. doi: 10.1177/0004867416660200. No abstract available.

Neuromuscular Impairments Are Associated With Impaired Head and Trunk Stability During Gait in Parkinson Fallers.

Cole MH, Naughton GA, Silburn PA.

Neurorehabil Neural Repair. 2017 Jan;31(1):34-47.

Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations.

Hampson NB, Kieburtz KD, LeWitt PA, Leinonen M, Freed MI.

Int J Neurosci. 2017 Mar;127(3):276-284. doi: 10.1080/00207454.2016.1194274.

Neurotransmitter release: vacuolar ATPase V0 sector c-subunits in possible gene or cell therapies for Parkinson's, Alzheimer's, and psychiatric diseases.

Higashida H, Yokoyama S, Tsuji C, Muramatsu SI.

J Physiol Sci. 2017 Jan;67(1):11-17. Review.

Parkinson's disease-related network topographies characterized with resting state functional MRI.

Vo A, Sako W, Fujita K, Peng S, Mattis PJ, Skidmore FM, Ma Y, Uluğ AM, Eidelberg D.

Hum Brain Mapp. 2017 Feb;38(2):617-630. doi: 10.1002/hbm.23260.